Cristina Gasparetto, MD, Duke Cancer Institute

Articles by Cristina Gasparetto, MD, Duke Cancer Institute

Improving Care in Multiple Myeloma: Unmet Needs and Future Directions

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 25th 2022

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Use of CAR T-Cell Therapy in Earlier Lines in Multiple Myeloma

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 25th 2022

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

CAR T-Cell Therapy in RRMM: Adverse Event Management

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 18th 2022

Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy: KarMMa Study and the Role of Ide-Cel in RRMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 18th 2022

Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

CAR T-Cell Therapy: CARTITUDE-1 Study and the Role of Cilta-Cel in RRMM

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 11th 2022

Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.

Selection and Sequencing Of Bispecific Antibodies in RRMM and Key Takeaways

ByAjai Chari, MD, PhD,Krina K. Patel, MD, MSc, University of Texas MD Anderson Cancer Center,Cristina Gasparetto, MD, Duke Cancer Institute,Rafael Fonseca, MD,Omar Nadeem, MD

August 11th 2022

Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.